Camonsertib is a selective inhibitor of the TRK (tropomyosin receptor kinase) family of proteins, particularly targeting TRKA, TRKB, and TRKC. It is primarily developed for the treatment of cancers that harbor NTRK gene fusions, which are genetic abnormalities driving tumor growth in a variety of solid tumors. These fusions occur across multiple tumor types, including certain lung, thyroid, colorectal, and pediatric cancers.

The compound shows potent activity against both primary and resistance mutations in TRK genes, making it effective in patients who have progressed on prior TRK inhibitors. Its design allows for improved central nervous system penetration, which is critical for managing brain metastases commonly seen in advanced cancers.

Camonsertib is being evaluated in clinical trials for patients with advanced or metastatic solid tumors. Early data suggest durable responses and a manageable safety profile, positioning it as a promising therapeutic option in precision oncology, especially for tumors with limited treatment alternatives.